Comparing Anastrozole and Tamoxifen for Early Breast Cancer Treatment
Author Information
Author(s): Aydiner Adnan, Faruk Tas
Primary Institution: Istanbul University, Istanbul Medical School, Department of Medical Oncology, Istanbul, Turkey
Hypothesis
Is anastrozole more effective than tamoxifen in the adjuvant treatment of early breast cancer in postmenopausal women?
Conclusion
Anastrozole appears to have superior efficacy than tamoxifen in the adjuvant hormonal treatment of early breast cancer.
Supporting Evidence
- The combined hazard rate for event-free survival was 0.77 for patients treated with anastrozole compared to tamoxifen.
- Anastrozole showed a significant improvement in event-free survival rates over tamoxifen.
- Switching to anastrozole after tamoxifen treatment resulted in better outcomes.
Takeaway
This study found that anastrozole works better than tamoxifen for treating early breast cancer in women who have gone through menopause.
Methodology
Systematic review and meta-analysis of randomized-controlled trials comparing anastrozole with tamoxifen.
Potential Biases
Potential bias due to differences in patient populations and study designs across trials.
Limitations
The low number of trials included in the analysis limits definitive conclusions.
Participant Demographics
Postmenopausal women with early breast cancer, primarily estrogen receptor-positive.
Statistical Information
P-Value
<0.0001
Confidence Interval
0.70–0.85
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website